Acute and delayed emesis after cisplatin-based regimen: description and prevention.
Lorazepam, dexamethasone and high-dose metoclopramide were given to 54 patients to prevent emesis induced by cisplatin (50-120 mg/m2) on day 1, while prochlorperazine and dexamethasone were administered on days 2 and 3 for control of delayed emesis. Nausea and emesis were recorded from day 1 to day 8. This combination was well tolerated. Prevention on day 1 was complete for 72% of patients and satisfactory (less than or equal to 2 emeses on day 1) in 85%. From days 2 to 8, no emesis, less than or equal to 2 and greater than 2 episodes occurred in 70, 11 and 19%, respectively. Overall control (days 1-8) was complete in 55.5% and satisfactory (less than or equal to 2 emeses on day 1 and/or less than or equal to 2 emeses from days 2 to 8) in 74%. Delayed emesis started on days 2-5. Mean duration was 2.6 days. Delayed nausea or emesis were more frequent when emesis occurred on day 1. Based on data previously reported and on these observations, better ways to prevent delayed events are discussed. Further trials must record systematically delayed side effects.
Louvet
C
C
Division of Hemato-Oncology, Hôtel-Dieu de Montréal Hospital, Qué., Canada.
Lorange
A
A
Letendre
F
F
Beaulieu
R
R
Pretty
H M
HM
Courchesne
Y
Y
Neemeh
J A
JA
Monte
M
M
Latreille
J
J
D000208:Acute Disease; D000932:Antiemetics / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use; D008787:Metoclopramide / Q000627:therapeutic use; D009325:Nausea / Q000139:chemically induced* / Q000517:prevention & control; D011346:Prochlorperazine / Q000627:therapeutic use; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control
D000932:Antiemetics; D003907:Dexamethasone; D008787:Metoclopramide; D008140:Lorazepam; D002945:Cisplatin; D011346:Prochlorperazine